Preventing sensory and motor issues in children undergoing chemotherapy
Preventing Sensory and Motor Dysfunctions in Children Receiving Neurotoxic Chemotherapy - a Randomized Controlled, Multi-center Trial
This study is testing a fun training program to see if it can help kids aged 6-18 avoid nerve problems while they are getting chemotherapy.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 131 (estimated) |
| Ages | 6 Years to 18 Years |
| Sex | All |
| Sponsor | University of Basel Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 2 sites (Basel and 1 other locations) |
| Trial ID | NCT05606588 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to evaluate the effectiveness of a playful sensorimotor training program in preventing chemotherapy-induced peripheral neuropathy in children aged 6-18 years. The study will involve a multicenter, randomized controlled design where participants will be divided into an intervention group receiving the training alongside standard care and a control group receiving standard care only. Data will be collected at multiple time points to assess the impact of the intervention on sensory and motor functions. The trial will recruit 131 patients from seven different centers across Switzerland and Germany.
Who should consider this trial
Good fit: Ideal candidates are children aged 6-18 years scheduled to receive neurotoxic chemotherapy with platinum derivatives or vinca-alkaloids.
Not a fit: Patients with known neuropathies from other causes or disabilities that hinder understanding of the training instructions may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve the quality of life and motor development in children receiving neurotoxic chemotherapy.
How similar studies have performed: Previous studies have shown promising results with exercise interventions for similar conditions, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * All tumor patients, aged 6-18 years, who are scheduled to receive neurotoxic chemotherapy with a platinum-derivate or vinca- alkaloid (e.g. vincristine, vinblastin mono, carboplatinum, cisplatin). Exclusion Criteria: * Exclusion criteria are known neuropathies of other cause (e.g. diabetes), disabilities or lack of German language that prevent the understanding of the informed consent as well as the instructions for training.
Where this trial is running
Basel and 1 other locations
- Kantonspital Aarau — Basel, Switzerland (Not_yet_recruiting)
- UKBB Kinderspital — Basel, Switzerland (Recruiting)
Study contacts
- Principal investigator: Fiona Streckmann, Dr. — University of Basel, Department of Sport, Exercise and Health
- Study coordinator: Fiona Streckmann, Dr.
- Email: fiona.streckmann@unibas.ch
- Phone: 061 207 47 30
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.